Skip to content

A Clinical trial to study effectiveness of newly designed appliance for Oral submucous fibrosis.

Comparative efficacy a newly designed physio-therapeutic appliance for the treatment of Oral Sub-Mucous Fibrosis

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/06/034307
Enrollment
82
Registered
2021-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K135- Oral submucous fibrosis

Interventions

Intervention1: â?¢ The intervention in this study is an innovative novel physiotherapeutic appliance. â?¢The participants in the trial will be treated with Intralesional injections of Dexamethasone &

Sponsors

DBT ATGC PROGRAM
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Adverse history of chronic chewing habits of areca nut, tobacco, or both for more than 2 years. 2. The patients with reduced mouth opening having a maximal mouth opening range of 20-34mm. 3. Patients of age group between 18-40 years will be enrolled. Both adult males and females will be recruited. In the adults above the age of 40 years pathological periodontal diseases are observed, hence age will be limited up to 40 years. 4. Teeth present central incisor to the second molar in all quadrants with good periodontal health.

Exclusion criteria

Exclusion criteria: 1.Trismus owing to diseases other than OSMF such as a. Systemic diseases like sclerosis, tetany, b. Odontogenic causes like pericoronitis, third molar removal, c. TMJ disorder or masticatory apparatus dysfunction, d. Non-odontogenic infection- Meningitis, Tetanus, Peritonsillar / Parotid abscess 2. Presence of other mucosal diseases (oral cancer, lichen planus, and leukoplakia), 3. Any active odontogenic infection causing swelling/pain or trismus. 4. Subjects having periodontal diseases like pyorrhea will not be included. 5. Patients should not have taken any prior treatment for the OSMF. 6. Presence of any deleterious habit (e.g., bruxism), 7. Patient with partial edentulism. 8. Patients with psychotic behavior or not willing to comply with the treatment protocol & follow-up will be excluded.

Design outcomes

Primary

MeasureTime frame
To assess the impact of Novel physiotherapeutic appliance in the treatment of OSMF in terms of change in maximal mouth openingTimepoint: Each patients treatment will last 8 weeks, with patients being seen twice a week and followed up on twice a month for 3 months. Thus total duration for assessment is for 5 months. Each patient will be evaluated at the baseline, every 8-week care session, and every 15 days for the next three months. Thus a total of 22 progressive assessments at each visit.

Secondary

MeasureTime frame
To assess change in Quality of life (QOL) by improvement in Inter-Incisal Distance (IID) by physiotherapyTimepoint: For qualitative assessment, regarding Quality of Life, a standardized questionnaire will be evaluated between the comparative A and B group by the Research associate at pretreatment, after 8 weeks of treatment and at the end of the treatment for the individual patients. Five points â??Likert rating scaleâ?? has been added in the questionnaire to get the quantitative assessment. The patient will give a score of his/ her condition at initial and subsequent follow up, which will be noted.

Countries

India

Contacts

Public ContactDr Atul P Sattur

SDM College of Dental Sciences and Hospital

atulsattur@gmail.com9886215957

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026